Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848857 | 0.92 | EPHX2 (0.45) | EPHX2NR1H4DDR1ELANEHDAC1 | |
| SCHEMBL25848961 | 0.90 | TRPV1 (0.48) | EPHX2NR1H4DDR1ELANEHDAC1 | |
| SCHEMBL24196659 | 0.89 | MCL1 (0.42) | EPHX2NR1H4DDR1ELANEHDAC1 | |
| SCHEMBL25848940 | 0.83 | LSS (0.50) | EPHX2NR1H4HDAC1HDAC6HDAC4 | |
| SCHEMBL30393777 | 0.83 | ELANE (0.43) | EPHX2ELANEHDAC1HDAC6HDAC4 | |
| SCHEMBL24196156 | 0.83 | ELANE (0.43) | EPHX2ELANEHDAC1HDAC6HDAC4 | |
| SCHEMBL25304798 | 0.83 | NAMPT (0.41) | EPHX2DDR1ELANEHDAC1HDAC6 | |
| SCHEMBL25848848 | 0.82 | EPHX2 (0.48) | EPHX2NR1H4DDR1HDAC1HDAC6 | |
| SCHEMBL25848869 | 0.82 | ELANE (0.39) | EPHX2ELANEHDAC1HDAC6HDAC4 | |
| SCHEMBL25848856 | 0.81 | EPHX2 (0.43) | EPHX2NR1H4DDR1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4175624-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-116075297-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | EPHX2 2590/4885NR1H4 3085/4885DDR1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.